ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

INMB INmune Bio Inc

11,29
0,45 (4,15%)
27 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
INmune Bio Inc INMB NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,45 4,15% 11,29 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
10,83 10,83 11,73 11,29 10,84
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
25.4.202415:00GLOBEINmune Bio Inc. Announces $9.7 Million Registered Direct..
23.4.202414:00GLOBEINmune Bio Inc. Announces 24-Month Stability Validation of..
22.4.202414:00GLOBEINmune Bio Inc. Raises Approximately $4.8 Million in Gross..
08.4.202414:00GLOBEINmune Bio Inc. Presents Data on INB03’s Role as an Immune..
28.3.202421:01GLOBEINmune Bio Inc. Announces Year End 2023 Results and Provides..
26.3.202421:01GLOBEINmune Bio Inc. to Report Fourth Quarter 2023 Financial..
13.3.202413:00GLOBEINmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives..
05.3.202414:00GLOBEINmune Bio Reports Significant EEG Improvement in..
12.2.202415:00GLOBEINmune Bio to Participate in the Oppenheimer 34th Annual..
06.2.202415:00GLOBEINmune Bio to Participate in Baird’s Biotech Discovery..
30.1.202414:02EDGAR2Form 8-K - Current report
30.1.202414:00GLOBEINmune Bio Announces FDA Removal of Clinical Hold for..
16.1.202414:30GLOBEELEVAI Labs, Inc. Acquires Worldwide License Agreement for..
02.1.202422:00EDGAR2Form 8-K - Current report
02.1.202414:00GLOBEINmune Bio Announces First Patient Dosed in a Phase 1/2..
18.12.202322:15EDGAR2Form 8-K - Current report
18.12.202322:05EDGAR2Form 8-A12B/A - Registration of securities [Section 12(b)]:..
18.12.202322:01EDGAR2Form 8-K - Current report
18.12.202322:01GLOBEINmune Bio Provides Update Regarding Global Alzheimer’s..
29.11.202322:00EDGAR2Form 8-K - Current report
29.11.202314:00GLOBEINmune Bio Inc. Demonstrates that INB03 Enhances the Uptake..
27.11.202322:00EDGAR2Form 8-K - Current report
27.11.202314:00GLOBEINmune Bio Receives EMA’s Authorization in France and Spain..
15.11.202322:13EDGAR2Form 8-K - Current report
15.11.202315:00GLOBEINmune Bio Inc. Announces Expansion of Phase II Clinical..
13.11.202317:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.11.202321:13EDGAR2Form 8-K - Current report
01.11.202321:10GLOBEINmune Bio Inc. Announces Third Quarter 2023 Results and..
01.11.202321:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31.10.202321:25EDGAR2Form 8-K - Current report
31.10.202313:00GLOBEINmune Bio Inc. Patent Claims Covering INB16 Cell Line and..
30.10.202314:07GLOBEINmune Bio Inc. Presents Preclinical Data at SITC 2023..
17.10.202314:00GLOBEINmune Bio Inc. Presents New Biomarker and Feasibility Data..
16.10.202315:00GLOBEINmune Bio Inc. to Report Third Quarter 2023 Financial..
07.9.202315:10EDGAR2Form 8-K - Current report
07.9.202315:00GLOBEINmune Bio Inc. to Present at Baird Global Healthcare..
05.9.202322:00EDGAR2Form 8-K - Current report
05.9.202314:00GLOBEINmune Bio Inc. Announces Approval of Clinical Trial..
16.8.202322:41EDGAR2Form 8-K - Current report
16.8.202322:39EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08.8.202322:01EDGAR2Form 8-K - Current report
07.8.202322:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.8.202322:00GLOBEINmune Bio Inc. Announces Second Quarter 2023 Results and..
02.8.202312:02EDGAR2Form 8-K - Current report
01.8.202314:00GLOBEINmune Bio Inc. to Present at the BTIG Virtual ..
31.7.202314:00GLOBEINmune Bio, Inc. to Report Second Quarter 2023 Financial..
27.7.202322:43EDGAR2Form 8-K - Current report
14.7.202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.7.202322:00EDGAR2Form 8-K - Current report
12.7.202319:23EDGAR2Form 144 - Report of proposed sale of securities

Kürzlich von Ihnen besucht

Delayed Upgrade Clock